Press release
Deadline on July 20th coming up ion Lawsuit for Investors in Provention Bio, Inc. (NASDAQ: PRVB)
A Deadline is coming up on July 20, 2021 in the lawsuit for certain investors in Provention Bio, Inc. (NASDAQ: PRVB).
Investors who purchased shares of Provention Bio, Inc. (NASDAQ: PRVB) have certain options and there are strict and short deadlines running. Deadline: July 20, 2021. NASDAQ: PRVB stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges on behalf of purchasers of Provention Bio, Inc. (NASDAQ: PRVB) common shares between November 2, 2020 and April 8, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between November 2, 2020 and April 8, 2021, the defendants made false and/or misleading statements and/or failed to disclose that the teplizumab BLA was deficient in its submitted form and would require additional data to secure FDA approval, that accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed, that the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Provention Bio, Inc. (NASDAQ: PRVB) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on July 20th coming up ion Lawsuit for Investors in Provention Bio, Inc. (NASDAQ: PRVB) here
News-ID: 2317028 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for Provention
Type 1 Diabetes Therapeutic Pipeline Analysis | Insights into the Latest FDA, EM …
As per DelveInsight's assessment, globally, around 80+ key pharma and biotech companies are working on 100+ pipeline drugs in the Type 1 Diabetes therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Type 1 Diabetes Pipeline Insight, 2022" report by DelveInsight provides a…
Diabetes Market to Expand at a Significant Growth Rate During the Forecast Perio …
DelveInsight's "Diabetes Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diabetes Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Diabetes market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to…
Celiac Disease Drug Market Comprehensive Insight by Growth Rate, Industry Status …
The global celiac disease drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Celiac disease is an autoimmune disorder in which a protein called gluten damages the small intestine's membrane. Gluten can be present in grains such as rye, barley, and wheat. Gluten causes an immunological reaction that damages the villi in the small intestine (small finger-like projections in the small intestine which promote…
Investigation announced for Long-Term Investors in Provention Bio, Inc. (NASDAQ: …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Provention Bio, Inc..
Investors who are current long term investors in Provention Bio, Inc. (NASDAQ: PRVB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: PRVB stocks follows a lawsuit filed against Provention…
Players in Celiac Disease Drugs Market Focus on Adopting Partnership Strategies …
Coeliac disorder is a health condition in which your body attacks your digestive tissues when you consume gluten. This damages your small intestine (small intestine) due to the damage it can cause to your cells, so that you're not able to absorb nutrients properly. The most common food allergies in infants and toddlers are milk, peanuts, soy, wheat and eggs. The main reason young children suffer from a food allergy…
Lawsuit filed for Investors in shares of Provention Bio, Inc. (NASDAQ: PRVB)
An investor, who purchased shares of Provention Bio, Inc. (NASDAQ: PRVB), filed a lawsuit over alleged violations of Federal Securities Laws by Provention Bio, Inc.
Investors who purchased shares of Provention Bio, Inc. (NASDAQ: PRVB) have certain options and for certain investors are short and strict deadlines running. Deadline: July 20, 2021. NASDAQ: PRVB investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Red Bank, NJ based…
